Se‐Hoon Lee
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
Papers in
-
- Lung Cancer Treatments and Mutations 148
- Lung Cancer Diagnosis and Treatment 38
- Renal cell carcinoma treatment 15
- Oncology 125
- Cancer Immunotherapy and Biomarkers 72
- Lung Cancer Research Studies 22
- Co-authors
- Keunchil Park (138 shared papers)Myung‐Ju Ahn (141 shared papers)Jin Seok Ahn (125 shared papers)Jong‐Mu Sun (125 shared papers)Dae Seog Heo (122 shared papers)Tae Min Kim (100 shared papers)Dong‐Wan Kim (93 shared papers)Bhumsuk Keam (65 shared papers)
- Journals
- Cancer Research and Treatment (43 papers)Lung Cancer (32 papers)Journal of Thoracic Oncology (32 papers)Journal of Clinical Oncology (20 papers)Cancer (14 papers)
- Partner nations
- South KoreaUnited StatesUnited Kingdom
In The Last Decade
Se‐Hoon Lee
505 papers receiving 23.4k citations
Se‐Hoon Lee's Hit Papers
Peers
Comparison fields: 5 of 156
- Oncology 6.9k
- Pulmonary and Respiratory Medicine 9k
- Otorhinolaryngology 911
- Genetics 1.3k
- Cancer Research 1.8k
Countries citing papers authored by Se‐Hoon Lee
This map shows the geographic impact of Se‐Hoon Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Se‐Hoon Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Se‐Hoon Lee more than expected).
Fields of papers citing papers by Se‐Hoon Lee
This network shows the impact of papers produced by Se‐Hoon Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Se‐Hoon Lee. The network helps show where Se‐Hoon Lee may publish in the future.
Co-authors
The 25 scholars most cited alongside Se‐Hoon Lee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 527 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Hit paper breakdown → | 2020 | 890 |
| 2 | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Hit paper breakdown → | 2020 | 837 |
| 3 | Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort Hit paper breakdown → | 2016 | 720 |
| 4 | Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 711 |
| 5 | Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition Hit paper breakdown → | 2021 | 659 |
| 6 | Lung adenocarcinoma promotion by air pollutants Hit paper breakdown → | 2023 | 546 |
| 7 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Hit paper breakdown → | 2009 | 498 |
| 8 | Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas Hit paper breakdown → | 2017 | 397 |
| 9 | 2019 | 385 | |
| 10 | Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study Hit paper breakdown → | 2017 | 375 |
| 11 | Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) Hit paper breakdown → | 2019 | 300 |
| 12 | 2018 | 261 | |
| 13 | Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice Hit paper breakdown → | 2021 | 258 |
| 14 | 2012 | 241 | |
| 15 | 2005 | 235 | |
| 16 | 2019 | 215 | |
| 17 | 2017 | 214 | |
| 18 | Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer Hit paper breakdown → | 2022 | 211 |
| 19 | 2015 | 208 | |
| 20 | 2016 | 203 |
About Se‐Hoon Lee
Se‐Hoon Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Genetics, Cancer Research and Otorhinolaryngology, having authored 527 papers that have together received 23.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (148 papers), Cancer Immunotherapy and Biomarkers (72 papers), Glioma Diagnosis and Treatment (48 papers), Lung Cancer Diagnosis and Treatment (38 papers), Lung Cancer Research Studies (22 papers), Head and Neck Cancer Studies (20 papers), Cancer Genomics and Diagnostics (19 papers) and Renal cell carcinoma treatment (15 papers). The work is most often cited by research in Oncology (6.9k citations), Pulmonary and Respiratory Medicine (9k citations), Otorhinolaryngology (911 citations), Genetics (1.3k citations) and Cancer Research (1.8k citations). Se‐Hoon Lee has collaborated with scholars based in South Korea, United States and United Kingdom. Frequent co-authors include Keunchil Park, Myung‐Ju Ahn, Jin Seok Ahn, Jong‐Mu Sun, Dae Seog Heo, Tae Min Kim, Dong‐Wan Kim, Bhumsuk Keam, Yung‐Jue Bang and Doo Hyun Chung. Their work appears in journals such as Cancer Research and Treatment, Lung Cancer, Journal of Thoracic Oncology, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.